Reiko Namikawa

US Patent:

54117496, May 2, 1995

Filed:

Dec 23, 1992

Appl. No.:

7/996831

Inventors:

Susan K. Mayo - Portland OR
Reiko Namikawa - Palo Alto CA
Hideto Kaneshima - Palo Alto CA
Joseph M. McCune - San Francisco CA

Assignee:

Systemix, Inc. - Palo Alto CA

International Classification:

A61K 3500
A61K 3900
A61K 4900

US Classification:

424578

Abstract:

Human lymphoid tissue is introduced into an immunocompromised host to provide opportunities to investigate the effect of stimuli on the human immune system and obtain information and products from the stimulus. Particularly, methodology is provided for the production of human monoclonal antibodies by introducing lymphoid tissue into an immunocompromised host, stimulating the B-lymphocytes with an appropriate immunogen, harvesting the tissue and immortalizing and/or cloning the B-lymphocytes under conditions to obtain a stable supply of monoclonal antibodies.

US Patent:

60938722, Jul 25, 2000

Filed:

Feb 13, 1992

Appl. No.:

7/836195

Inventors:

Hideto Kaneshima - Palo Alto CA
Reiko Namikawa - Palo Alto CA
Joseph McCrary McCune - San Francisco CA

Assignee:

Systemix, Inc. - Palo Alto CA

International Classification:

A01K 6700
C12N 500

US Classification:

800 8

Abstract:

A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.

US Patent:

54769973, Dec 19, 1995

Filed:

May 17, 1994

Appl. No.:

8/245250

Inventors:

Hideto Kaneshima - Palo Alto CA
Reiko Namikawa - Palo Alto CA
Joseph M. McCune - San Francisco CA

Assignee:

Systemix, Inc. - Palo Alto CA

International Classification:

A61K 3500

US Classification:

800 2

Abstract:

A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.

US Patent:

56334265, May 27, 1997

Filed:

Feb 10, 1994

Appl. No.:

8/194717

Inventors:

Reiko Namikawa - Palo Alto CA
Seishi Kyoizumi - Hiroshima, JP
Joseph M. McCune - San Francisco CA
Hideto Kaneshima - Palo Alto CA

Assignee:

Systemix, Inc. - Palo Alto CA

International Classification:

A61K 4900
A61K 4800

US Classification:

800 2

Abstract:

Chimeric immunocompromised hosts are provided, comprising human bone marrow of at least 4 weeks from the time of implantation. The bone marrow is found to assume the normal population of bone marrow except for erythrocytes. The bone marrow may be used to study the effect of various agents on the proliferation and differentiation of hematopoietic cells.

US Patent:

56251270, Apr 29, 1997

Filed:

May 4, 1995

Appl. No.:

8/434706

Inventors:

Hideto Kaneshima - Palo Alto CA
Reiko Namikawa - Palo Alto CA
Joseph M. McCune - San Francisco CA

Assignee:

SyStemix, Inc. - Palo Alto CA

International Classification:

A61K 3500

US Classification:

800 2

Abstract:

A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.

US Patent:

56435517, Jul 1, 1997

Filed:

Oct 26, 1994

Appl. No.:

8/329679

Inventors:

Reiko Namikawa - Palo Alto CA
Seishi Kyoizumi - Aki-gun, JP
Emilya Shtivelman - Belmont CA
Joseph M. McCune - San Francisco CA

Assignee:

Systemix, Inc. - Palo Alto CA

International Classification:

A01N 5700
A61K 3800
C12N 500
C12N 1506

US Classification:

424 91

Abstract:

A method for initiating metastasis of human tumor cells under experimental conditions is provided. Immunocompromised non-human mammals having a viable, xenogeneic organ or tissue are used as a host for human tumor cells. The cells are introduced into the chimeric animal after the solid tissue is implanted and are then able to grow and metastasize as they would in situ. Therapeutic regimens may be evaluated in this system to determine efficacy against metastatic processes.

US Patent:

56120184, Mar 18, 1997

Filed:

Jan 18, 1994

Appl. No.:

8/183178

Inventors:

Mark L. Bonyhadi - Belmont CA
Hideto Kaneshima - Palo Alto CA
Joseph M. McCune - San Francisco CA
Reiko Namikawa - Palo Alto CA
Lishan Su - Palo Alto CA

Assignee:

Systemix, Inc. - Palo Alto CA

International Classification:

A61K 4900

US Classification:

424 92

Abstract:

A method is provided for screening compounds for the ability to supress thymocyte depletion in thymuses of HIV-infected individuals, particularly enhancing the CD4. sup. + -expressing population as compared to an untreated individual. Particularly, drugs are provided which allow for this result, cyclosporine A being exemplary.